PCSK9 participates in oxidized‐low density lipoprotein‐induced myocardial injury through mitochondrial oxidative stress and Drp1‐mediated mitochondrial fission

Oxidized low-density lipoprotein (ox-LDL), derived from low-density lipoprotein (LDL) under oxidative stress, is a crucial risk factor in the initiation and development of various cardiovascular diseases.1 Although we have quite recently reported that ox-LDL/LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1) induced cardiac hypertrophy in mice,2 whether ox-LDL impairs cardiac function directly in vivo remains elusive. In this study, we reveal that proprotein convertase subtilisin/kexin type 9 (PCSK9) contributes to ox-LDL-LOX-1-induced myocardial damage via increasing oxidative stress and mitochondrial fission. PCSK9, a liver-derived secretory protease, promotes the LDL-R degradation to maintain cholesterol homeostasis.3 Besides the modulating of LDL and ox-LDL receptor turnover, PCSK9 is constitutively expressed in cardiomyocytes4 and is implicated to exert extrahepatic effects in the heart.5–7 In this study, C57BL/6J mice subjected to intraperitoneal injection of ox-LDL for 4 weeks showed significant cardiac hypertrophy and dysfunction (Figure S1), prominent myocardial apoptosis (Figure S2A,B), increased myocardial oxidative stress and Drp-1-mediated mitochondrial fission (Figure S3A–D), accompanied by elevated PCSK9 levels in serum and heart (Figure 1B,D). Similarly, in cultured adult and neonatal mouse ventricular myocytes (AMVMs and NMVMs), ox-LDL also induced oxidative stress (Figure S3E,G), mitochondrial dysfunction (Figure S3F,H,I–J), apoptosis (Figure S2C,D) and PCSK9 upregulation (Figure 1C,E; Figure S4A). Furthermore, a positive correlation between ox-LDL and PCSK9 levels was obtained in the serum of patients with hyperlipidemia and heart failure (Figure 1A). To confirm the involvement of PCSK9 in cardiac hypertrophy and function, a PCSK9 inhibitor evolocumab was administered to ox-LDL-treated mice. No significant difference was observed in cardiac hypertrophy or function between control mice and evolocumab-administrated mice. Administration of evolocumab alleviated the hypertrophic response in ox-LDL-treated hearts, as revealed by reduced LV internal dimension, LV wall thickness (Figure 1F), HW/BW (Figure 1H), cardiomyocyte size (Figure 1I), levels of Hypertrophy gene (Figure 1J) and fibrosis (Figure S4B). In addition, evolocumab improved cardiac function, as demonstrated by increased LVEF (Figure 1F), max dP/dt and min dP/dt (Figure 1G). These data indicate that cardiac hypertrophy and dysfunction induced by ox-LDL were attenuated in evolocumab-administered mice compared to control mice. Subsequently, we explored whether PCSK9 was involved in ox-LDL-induced myocardial apoptosis. Administration of evolocumab decreased the TUNEL-positive nuclei number in the myocardium, the expression of apoptosis markers such as cleaved caspase-3, cleaved caspase-9 and Bax, while upregulated Bcl-2 expression (Figure 2A–D). Consistently, in NMCMs, PCSK9 inhibition by two different approaches, pharmaceutic intervention by evolocumab or genetic intervention by shRNA adenovirus, reduced ox-LDL-induced cardiomyocyte apoptosis as evidenced by attenuated TUNEL staining and mitigated the related apoptotic signalling pathways (Figure 2E–L). The mitochondria constitute approximately 30% of the cardiomyocyte mass.8 The health of mitochondria is ensured by quality control mechanisms, including mitochondrial fission and fusion, while disruption of these processes leads to mitochondrial dysfunction and triggers oxidative stress and apoptosis.9 Therefore, we examined mitochondrial oxidative stress and fission in mice hearts. Our results showed that evolocumab counteracted the detrimental effects of ox-LDL, as reflected by lower levels of myocardial ROS (Figure 3A) and less mitochondrial fission as demonstrated by the elevated mean size of mitochondria, reduced percentage of mitochondria less than 0.4 μm2 and elevated percentage of mitochondria more than 0.8 μm2 (Figure 3B,C). Evolocumab treatment attenuated ox-LDL-enhanced Drp1 phosphorylation at S616 and elevated ATP content in ox-LDL-treated hearts (Figure 3D,E). In agreement with our in vivo results, in cultured NMCMs and AMVMs incubated with ox-LDL, mtROS levels and mitochondrial fragmentation degrees were markedly lower after treatment with evolocumab (Figure 3F–H,J). Meanwhile, the ox-LDL induced Drp1 phosphorylation at S616 was markedly mitigated, and mitochondrial membrane potential and ATP content were increased in evolocumab-treated NMCMs compared with vehicle-treated NMCMs (Figure 3I,K). These results imply that inhibition of PCSK9 alleviates ox-LDL-induced mtROS and mitochondrial impairment in cardiomyocytes. Coherently, similar to the results obtained from evolocumab-treated NMCMs, NMCMs treated with PCSK9 shRNA adenovirus also showed improved mitochondrial function (Figure S5). Since LOX-1, a main ox-LDL receptor, is recently found that it regulates PCSK9 in vascular tissues,10 we postulate that it mediates the synergistic effects of ox-LDL and PCSK9 in the heart. In ox-LDL-treated mouse hearts, the expression of LOX-1 was upregulated (Figure S6A). We then knockdown LOX-1 in mouse hearts by adeno-associated virus serotype 9 (AAV9) (Figure S6B,C). As expected, AAV9-shLOX-1 not only notably mitigated ox-LDL-induced LOX-1 expression, but also reduced PCSK9 expression in vivo (Figure 4F; Figure S6D). In line with that effect, knockdown of LOX-1 diminished cardiac hypertrophy induced by ox-LDL, as demonstrated by reduced LV internal dimension, wall thickness (Figure 4A), HW/BW (Figure 4C), cardiomyocyte size (Figure 4D), mRNA expression of ANP, BNP and β-MHC and fibrosis (Figure S6E–F, Figure 4E). Consistently, knockdown of LOX-1 improved cardiac function in ox-LDL-treated mice as indicated by increased LVEF (Figure 4A), max dP/dt, and min dP/dt (Figure 4B). Moreover, knockdown of LOX-1 also alleviated myocardial apoptosis, mitochondrial oxidative stress and fission in mice treated with ox-LDL (Figures S6G–J and S7). These results collectively suggest that LOX-1 is involved in ox-LDL-induced increases in PCSK9 expression, mitochondrial oxidative stress and fission, cardiomyocyte apoptosis and cardiac injuries. Although PCSK9 is produced mainly in livers, our study indicates that cardiomyocyte is also an important source of PCSK9 during ox-LDL treatment, for increased PCSK9 expression in cardiomyocytes is found in vitro and in vivo when ox-LDL is applied. Our results suggest that the increase in serum concentration of PCSK9, at least in part, owes to the heart. However, ox-LDL can cause oxidative stress to other organs in addition to the heart, we therefore, cannot preclude the possibility that the liver also considerably causes the increase in serum concentration of PCSK9, especially considering the liver function is not taken into account in this study. Another limitation is, considering flow cytometry assessment is unavailable for cultured primary neonatal and adult cardiomyocytes, we used fluorescence quantification to quantify ROS (DHE, MitoSOX). Although this method is widely applied, it should be noteworthy that the subjective assessment using it may occur and lead to bias, thus other relevant methods such as quantifying protein carbonyls in isolated mitochondria, are warranted to corroborate our findings in future studies. In summary, this study reports the effects of ox-LDL on cardiac remodelling through PCSK9 for the first time. Ox-LDL increases PCSK9 expression, mitochondrial oxidative stress, mitochondrial fission and cardiomyocyte apoptosis, leading to cardiac hypertrophy and dysfunction, while PCSK9 inhibition by pharmaceutical or genetic manners markedly alleviated the deleterious effects of ox-LDL on cardiomyocytes. In addition, LOX-1 mediates the bidirectional interaction between ox-LDL and PCSK9. The cardioprotection induced by PCSK9 inhibition provides support to the potential of PCSK9 as a new target for cardiac hypertrophy and associated heart failure therapy. This work was supported by the National Natural Science Foundation of China (81730009, 81941002, 82170389, 81670228 and 81770274) and Laboratory Animal Science Foundation of Science and Technology Commission of Shanghai Municipality (201409004300, 21140904400). The authors declare no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.